Lexaria Eyes GLP-1 Deals After FDA Clears Foundayo Oral Tablet with 12.4% Weight Loss
FDA approved Eli Lilly’s Foundayo oral GLP-1 agonist, marking the third FDA-approved oral treatment and delivering 27.3-pound (12.4%) average weight loss over 72 weeks. Lexaria’s DehydraTECH platform has achieved a 47.9% reduction in adverse events for oral semaglutide, positioning it for partnerships on GLP-1 drugs.
1. FDA Approves Eli Lilly’s Foundayo Oral GLP-1
The FDA has cleared Eli Lilly’s Foundayo (orforglipron) oral GLP-1 agonist for adult obesity and weight-related conditions, the third FDA-approved oral GLP-1 after Rybelsus and Wegovy tablets. In a 72-week trial, subjects lost an average 27.3 pounds (12.4%) and can dose anytime, unlike competitors requiring empty-stomach intake.
2. Lexaria’s DehydraTECH Reduces GLP-1 Side Effects
Lexaria’s DehydraTECH platform demonstrated a 47.9% reduction in adverse events with oral semaglutide versus Rybelsus in Study GLP-1-H24-4, highlighting potential to lower nausea and gastrointestinal issues across GLP-1 therapies. The technology is backed by 65 issued patents worldwide.
3. Future GLP-1 Testing and Partnership Plans
Lexaria plans DehydraTECH testing with additional GLP-1 candidates including retatrutide and amycretin in 2026 and is evaluating orforglipron processing, aiming to secure collaboration deals with leading pharmaceutical companies to expand oral GLP-1 offerings while improving patient experience.